Parmax Pharma posts Q1 FY 23 loss at Rs. 1.31 Cr

The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022

Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr

The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.

SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr

The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Vascular experts establish appropriate use of IVUS in peripheral interventions

Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions

Roche gets USFDA approval of Xofluza to treat influenza in children

Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age

Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine

Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA

Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors

Company creates Younger T Cells for fighting cancer using its NR2F6 technology

Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean

Congenica announces partnership with Avesthagen

New deal strengthens Congenica’s presence in India